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prior to Amplatzer device implantation. 3D was performed with transthoracic rotational 
acquisition at 3’ intervals (TomTec Echoscan 3.0). Diameters of defect, predicted mean 
diameter and drea were measured by TEE and 3D. Results were compared to stretched 
balloon diameter and final Amplatzer waist diameter. All patients underwent successful 
implantation procedure wthout residual leaks after 6 months. 
Results. Quality of 3D was good in 11 pts and satisfactory in 7. Mean stretched/ 
Amplatzer diameter was 20r5/22+5mm and stretched/Amplatzer waist area 3.2t1.61 
3.9k2.0 cm2. Maximal diameters were severely underestimated by TEE and not by 3D: 
14*4 vs 23*5 mm (p<O.OOl), with calculated areas of 1.2i0.6 vs 2.9+1.5cm2 resp. 
(p<O.OOl). 30 had good correlation and close agreement to stretch diameter (r=0,87) 
with small underestimation (3mm) of true size of implanted device. TEE underestimated 
defect size markedly by >6mm (r=0,59). 
1168-155 Systemic Dissemination of Nickel in Patients With Atrial Conclusions. Transthoracic 3D, as opposed to TEE, allows accurate transthoracic mea- 
Septal Defects Following the Implantation of the surements of ASD diameter and reliable prediction of Amplatzer size in young patients. 
Amplatzer Septal Occluder P-dimensional measurements significantly underestimate defect dimensions. 
Thomas Neumann, Draga Petkovic, Maria Burian. Michael W. Weber, Matthias Rau, 
Roland R. Brandt, Thorsten Dill, Christian Hamm, Kerckhoff Heart Center, Bad Nauheim, 
Germany, Johann-Wolfgang-Goethe-University, Frankfurt, Germany 
Background: Transcatheter techniques to close atrial septal defects with the 
AmplatzerTM Septal occluder or other devices have been used with increasing frequency 
during the last few years. Most of these devices contain a Nickel-titanium alloy (Nitinol). 
Several published in vitro and in viva studies on a dog model could demonstrate a dis- 
semination of Nickel into ambient tissue. However, there is no data available on the 
release and the time course of release of nickel due to in patients degradation of Nitinol 
implants used for closure of atrial septal closure devices.The purpose of this prospective 
in situ study was to investigate the systemic dissemination of nickel following transcathe- 
ter closure of atrial septal defects of the secundum type. Methods: Blood samples were 
obtained from 10 patients before, 1 week, 2 weeks, 4 weeks, 8 weeks and 24 weeks after 
the procedure. Additionally, blood samples were drawn from 5 healthy patients. Serum 
concentrations of nickel were determined using inductwely coupled plasma-mess spec- 
trometry (ICP-MS, detection limit 0,3 F g/l). Transoesophageal echocardiography and 
magnetic resonance imaging were performed in all patients before, 4 weeks and 24 
weeks after the implantation. Results: BaselIne concentrations of nickel in 9/10 patients 
were within the normal range (c2@ g/l) and comparable between both groups: 1,62* 
1 ,Oi k g/l in patients vs 1,66* 1,041” g/l in the control group. Serum nickel IeVelS raised 
continuously, showmg a peak value up to 15,@ @ wthin 4 weeks after the procedure. 
Nickel levels returned to normal serum concentrations after 24 weeks. During the follow- 
up two patients with a transitional residual shunt and higher nickel serum levels com- 
pared to the other patients (p=O,O2) were obsewed. Conclusion: Systematic dissemina- 
tion of Nickel after pecutaneous closure of atrial septal defects of the secundum type can 
be meassured in the blood serum samples. This observation may reflect the endotheliaz- 
ation process of the graft. 
1168-158 Long-Term Follow-Up (15-Year) Results of Balloon 
Coarctation Angioplasty in the Adolescent and Adult 
Patient 
1168-156 Is Echocardiographic Guidance Necessary for Device 
Closure of Patent Foramen Ovale? 
PhillIp Moore, Monica S. Divakaruni, University of California at San Francisco, San 
Francisco, CA 
Background: Transcatheter device closure of patent foramen ovale (PFO) has routinely 
been performed using transesophageal echocardiographic (TEE) guidance in addition to 
fluoroscopy. Echocardiographic guidance adds significant cost and potential risks to the 
procedure. Multiple studies allude to the fact that device closure can be performed with- 
out TEE guidance; however, none have compare outcomes of these two approaches. 
This repolt compares our experience of device PFO closure with and without TEE guid- 
ance. Methods: Data were collected retrospectively from hospital records of all patients 
who underwent transcatheter PFO closure between 9196 and 6102 at UCSF. Results: Out 
of 62 patients who had attempted PFO device closure, 27 (median age 46 years (18 to 
61) had TEE assisted fluoroscopic guidance, while the remaining 55 patients (median 
age 47 years (12 to 61) had fluoroscopic guidance alone. All attempts were successful. 
Of those implanted with TEE guidance, the mean procedure time was 116 + 32 minutes 
with a mean fluoroscopy time of 33 + 15 minutes. Those without TEE guidance had a 
procedure time of 106 + 32 minutes and a fluoroscopy time of 26+ 20 minutes, not signif- 
icantly different. The rate of immediate post-procedure residual right to left shunt by right 
atrial angiogram was small or trivial in 9123 (39%) without TEE compared to 15/54 (26%) 
with TEE. The rate of right to left shunting at discharge defined by saline contrast with 
valsalva on transthoracic echocardiogram was 6127 (30%) in the TEE group and 17154 
(31%) in the non TEE group. Minor complications were seen in 3127 in the TEE group, 
none related to the TEE. One patient in the non TEE group had a minor complication 
necessitating transthoracic echocardiogram during the procedure. Conclusions: These 
data indicate that transcatheter device PFO closure may be safely and effectively per- 
formed with only fluoroscopic guidance with equivalent results to that with TEE assisted 
fluoroscoplc guidance. The elimination of echo support for this procedure may signifi- 
cantly reduce cost and complexity of the procedure. 
1168-157 Transthoracic 3-D Echocardiography Improves the 
Quantification of Atrial Septal Defect Size Before 
Amplatzer Closure 
Jaroslaw D. Kasprzak, Andrzej Sysa, Maria Krzeminska-Pakula, Michal Ciesielczyk, 
Pawel Dryzek. Jadwiga Mall, Josef Masura, Jaroslaw Drozdz, Medical University of 
Lodz, Poland, Lodz. Poland, Polish Mother’s Health Centre, Lodz, Poland, Lodz, Poland 
Aim of the study was to compare transthoracic three-dimensional echocardiography (3D) 
with transesophageal 2-dimensional echo (TEE) for the evaluation of secundum atrial 
septal defect (ASD) before intewentional closure with Amplatzer device 
Method. 16 children and young adults (3-20 years, 11*6) were studied with 3D and TEE 
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Saudi Arabia 
The long-term results of balloon angioplasty (BA) of coarctation of the aorta (Con) in 
adolescent and adult patients (pts) have not been well characterized. 
Methods: Between July 1966 and July 2001, 51 consecutive pts (36 male) underwent 
BA for native CoA. Their ages ranged from 15-55 (mean 22 f 7) yrs. One to 15 years fol- 
low-up data using repeat cardiac catheterization at one year and clinical examination and 
magnetic resonance imaging (MRI) annually up to 15 years form the basis of this study. 
Paired t-test was used to compare data before and after BA and at follow-up. P < 0.05 
was consldered significant. 
Results: No early or late deaths occurred. Peak coarctation gradient (PCG) decreased 
from 65 * 23 (mean * SD) to 10.4 f 7.3 mmHg (P < 0.0001). Restenosis defined as gra- 
dient > POmmHg across CoA occurred in 4 pts (7.6%). 3 of whom underwent redilation 6 
months later, and one underwent surgery. There was further drop in PCG at follow-up 
catheterization 12 months later to 7.2 f 7.9 mmHg (P < 0 05). Aneurysm was noted in 4 
pts (6%); in 3 of them the aneurysm was very small. One pt underwent surgical repair for 
medium size aneurysm one year later. 49 pts were followed-up by MRI for l-15 (mean 
7.4 f 4) years. No new aneurysm or recoarctation was noted and no Increase of the size 
of the 3 small aneurysms on follow-up MRI up to 15 years. Blood pressure was normal 
without medication in 31 pts (63%). 
Conclusions: BA for native CoA is safe and effective procedure. Its long-term results 
are satisfactory and should be the first option for treatment of native CoA in adults. 
1168-159 Fate of Infants With Severe Coarctation of Aorta Treated 
Early With Balloon Angioplasty: A 19-Year Study 
Jose SuBrez de Lezo, Alfonso Medina, Manuel Pan, Miguel Romero, Jose Segura, Luis 
Burgos. Antonio Delgado, Djordje Pavlovic, Marcos Rodriguez. Juan MuAoz, Carmen 
Rus, Fsderico Segura, ReIna Sofia Hospital, Cdrdoba, Spain, Dr. Negrin Hospital, Las 
Palmas, Spain 
Background: Infants with coarctation of aolfa (Con) presenting wth heart failure may be 
palliated by balloon angioplasty. However, controversy still persists regarding the useful- 
ness of this procedure and there is no informatlon on the need for further treatments until 
reaching adulthood. Methods:This study analyses the long-term evolution of a series of 
54 infants with severe CoA treated by balloon angioplasty, 35 of them (65%) had CISSoci- 
ated malformations and 3 had previous surgery. The mean age at first treatment was I+1 
months; 34 of them were neonates. ReSults:The significant reduction of gradient always 
improved the clinical condition, leadlng to prevent the need for surgery at this early stage 
in 35 (65%). However, initial mortality was 16% (n=9). Following this palliation the long- 
term evolution (IO+6 years) of survivors and the need for a second, third of fourth proce- 
